OBJECTIVE: To examine incidence and survival patterns of acral lentiginous melanoma (ALM) in the United States. DESIGN: Population-based registry study. We used the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute to evaluate data from 17 population-based cancer registries from 1986 to 2005. PARTICIPANTS: A total 1413 subjects with histologically confirmed cases of ALM. Main Outcome Measure Incidence and survival patterns of patients with ALM. RESULTS: The age-adjusted incidence rate of ALM overall was 1.8 per million person-years. The proportion of ALM among all melanoma subtypes was greatest in blacks (36%). Acral lentiginous melanoma had 5- and 10-year melanoma-specific survival rates of 80.3% and 67.5%, respectively, which were less than those for all cutaneous malignant melanomas overall (91.3% and 87.5%, respectively; P < .001). The ALM 5- and 10-year melanoma-specific survival rates were highest in non-Hispanic whites (82.6% and 69.4%), intermediate in blacks (77.2% and 71.5%), and lowest in Hispanic whites (72.8% and 57.3%) and Asian/Pacific Islanders (70.2% and 54.1%). Acral lentiginous melanoma thickness and stage correlated with survival according to sex and in the different racial groups. CONCLUSIONS: Population-based data showed that ALM is a rare melanoma subtype, although its proportion among all melanomas is higher in people of color. It is associated with a worse prognosis than cutaneous malignant melanoma overall. Hispanic whites and Asian/Pacific Islanders have worse survival rates than other groups, and factors such as increased tumor thickness and more advanced stage at presentation are the most likely explanations.
OBJECTIVE: To examine incidence and survival patterns of acral lentiginous melanoma (ALM) in the United States. DESIGN: Population-based registry study. We used the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute to evaluate data from 17 population-based cancer registries from 1986 to 2005. PARTICIPANTS: A total 1413 subjects with histologically confirmed cases of ALM. Main Outcome Measure Incidence and survival patterns of patients with ALM. RESULTS: The age-adjusted incidence rate of ALM overall was 1.8 per million person-years. The proportion of ALM among all melanoma subtypes was greatest in blacks (36%). Acral lentiginous melanoma had 5- and 10-year melanoma-specific survival rates of 80.3% and 67.5%, respectively, which were less than those for all cutaneous malignant melanomas overall (91.3% and 87.5%, respectively; P < .001). The ALM 5- and 10-year melanoma-specific survival rates were highest in non-Hispanic whites (82.6% and 69.4%), intermediate in blacks (77.2% and 71.5%), and lowest in Hispanic whites (72.8% and 57.3%) and Asian/Pacific Islanders (70.2% and 54.1%). Acral lentiginous melanoma thickness and stage correlated with survival according to sex and in the different racial groups. CONCLUSIONS: Population-based data showed that ALM is a rare melanoma subtype, although its proportion among all melanomas is higher in people of color. It is associated with a worse prognosis than cutaneous malignant melanoma overall. Hispanic whites and Asian/Pacific Islanders have worse survival rates than other groups, and factors such as increased tumor thickness and more advanced stage at presentation are the most likely explanations.
Authors: N Cascinelli; S Zurrida; V Galimberti; C Bartoli; R Bufalino; I Del Prato; L Mascheroni; A Testori; C Clemente Journal: J Dermatol Surg Oncol Date: 1994-12
Authors: Ricardo A Pollitt; Christina A Clarke; Susan M Swetter; David H Peng; John Zadnick; Myles Cockburn Journal: Cancer Date: 2010-08-24 Impact factor: 6.860
Authors: Lori A Pollack; Jun Li; Zahava Berkowitz; Hannah K Weir; Xiao-Cheng Wu; Umed A Ajani; Donatus U Ekwueme; Chunyu Li; Brian P Pollack Journal: J Am Acad Dermatol Date: 2011-11 Impact factor: 11.527
Authors: Yang Wang; Bin Lian; Lu Si; ZhiHong Chi; XiNan Sheng; Xuan Wang; LiLi Mao; BiXia Tang; SiMing Li; XieQiao Yan; Xue Bai; Li Zhou; ChuanLiang Cui; Jun Guo Journal: J Cancer Res Clin Oncol Date: 2021-02-21 Impact factor: 4.553